Drug Trial Radar · NCT07292441
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
224
Actual
Start
Jan 22, 2026
Primary completion
Sep 22, 2026
Study completion Sep 22, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight. In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.
Conditions
- Overweight or Obesity
Interventions
GZR18 injectionDrug
Used as specified in the protocol
PlaceboOther
Administered the same volume as GZR18
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change (%) from baseline in body weightTime frame: from Week 0 (W0) to Week 24 (W24)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Study site 01
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.